ATE355852T1 - Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten - Google Patents

Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten

Info

Publication number
ATE355852T1
ATE355852T1 AT03716821T AT03716821T ATE355852T1 AT E355852 T1 ATE355852 T1 AT E355852T1 AT 03716821 T AT03716821 T AT 03716821T AT 03716821 T AT03716821 T AT 03716821T AT E355852 T1 ATE355852 T1 AT E355852T1
Authority
AT
Austria
Prior art keywords
botulinum toxin
heart
treatment
circulatory diseases
mammal
Prior art date
Application number
AT03716821T
Other languages
English (en)
Inventor
Gregory F Brooks
Stephen Donovan
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28453838&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE355852(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE355852T1 publication Critical patent/ATE355852T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/043—Proteins; Polypeptides; Degradation products thereof
    • A61L31/047—Other specific proteins or polypeptides not covered by A61L31/044 - A61L31/046
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT03716821T 2002-04-01 2003-03-24 Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten ATE355852T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/114,740 US6767544B2 (en) 2002-04-01 2002-04-01 Methods for treating cardiovascular diseases with botulinum toxin

Publications (1)

Publication Number Publication Date
ATE355852T1 true ATE355852T1 (de) 2007-03-15

Family

ID=28453838

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03716821T ATE355852T1 (de) 2002-04-01 2003-03-24 Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten

Country Status (12)

Country Link
US (4) US6767544B2 (de)
EP (1) EP1490097B2 (de)
JP (3) JP2005521735A (de)
KR (1) KR20040105818A (de)
AT (1) ATE355852T1 (de)
AU (1) AU2003220511C1 (de)
BR (1) BR0308928A (de)
CA (1) CA2480505A1 (de)
DE (1) DE60312309T3 (de)
ES (1) ES2281636T5 (de)
MX (1) MXPA04009410A (de)
WO (1) WO2003084567A1 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6302875B1 (en) 1996-10-11 2001-10-16 Transvascular, Inc. Catheters and related devices for forming passageways between blood vessels or other anatomical structures
US6767544B2 (en) * 2002-04-01 2004-07-27 Allergan, Inc. Methods for treating cardiovascular diseases with botulinum toxin
US6977080B1 (en) * 1999-08-10 2005-12-20 Allergan, Inc. Intrapericardial botulinum toxin treatment for bradycardia
US20060216313A1 (en) * 1999-08-10 2006-09-28 Allergan, Inc. Methods for treating a stricture with a botulinum toxin
US6579847B1 (en) * 2000-05-01 2003-06-17 Imarx Therapeutics Inc. Method and apparatus for vascular neuromuscular blockade
WO2003059192A2 (en) 2001-12-21 2003-07-24 The Trustees Of Columbia University In The City Of New York C3 exoenzyme-coated stents and uses thereof for treating and preventing restenosis
US7022329B2 (en) * 2002-02-25 2006-04-04 Allergan, Inc. Method for treating neurogenic inflammation pain with botulinum toxin and substance P components
US20070135875A1 (en) * 2002-04-08 2007-06-14 Ardian, Inc. Methods and apparatus for thermally-induced renal neuromodulation
US20080213331A1 (en) 2002-04-08 2008-09-04 Ardian, Inc. Methods and devices for renal nerve blocking
US7653438B2 (en) 2002-04-08 2010-01-26 Ardian, Inc. Methods and apparatus for renal neuromodulation
US8150519B2 (en) 2002-04-08 2012-04-03 Ardian, Inc. Methods and apparatus for bilateral renal neuromodulation
US6978174B2 (en) 2002-04-08 2005-12-20 Ardian, Inc. Methods and devices for renal nerve blocking
US20070129761A1 (en) 2002-04-08 2007-06-07 Ardian, Inc. Methods for treating heart arrhythmia
US7617005B2 (en) 2002-04-08 2009-11-10 Ardian, Inc. Methods and apparatus for thermally-induced renal neuromodulation
US9636174B2 (en) 2002-04-08 2017-05-02 Medtronic Ardian Luxembourg S.A.R.L. Methods for therapeutic renal neuromodulation
AU2003259246A1 (en) * 2002-07-29 2004-02-16 Rajiv Doshi Methods for the use of neurotoxin in the treatment of urologic disorders
US20040226556A1 (en) 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
US8073538B2 (en) 2003-11-13 2011-12-06 Cardio Polymers, Inc. Treatment of cardiac arrhythmia by modification of neuronal signaling through fat pads of the heart
US6974579B2 (en) * 2004-01-08 2005-12-13 Allergan, Inc. Methods for treating vascular disorders
US7811584B2 (en) * 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US20060024331A1 (en) * 2004-08-02 2006-02-02 Ester Fernandez-Salas Toxin compounds with enhanced membrane translocation characteristics
EP1982997B1 (de) 2004-09-01 2012-08-08 Allergan, Inc. Abbaubare Clostridientoxine
US7906124B2 (en) * 2004-09-18 2011-03-15 Asthmatx, Inc. Inactivation of smooth muscle tissue
GB2419817A (en) * 2004-10-29 2006-05-10 Ipsen Ltd Treatment of cardiac fibrillation disorders
WO2006063199A2 (en) 2004-12-09 2006-06-15 The Foundry, Inc. Aortic valve repair
US9833618B2 (en) * 2005-02-04 2017-12-05 Palo Alto Investors Methods and compositions for treating a disease condition in a subject
CA2601592A1 (en) 2005-03-15 2006-09-28 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
WO2008036060A2 (en) 2005-04-05 2008-03-27 Allergan, Inc. Clostridial toxin activity assays
US9511210B2 (en) * 2006-05-19 2016-12-06 The Foundry, Llc Apparatus for toxin delivery to the nasal cavity
JP5826450B2 (ja) * 2005-07-22 2015-12-02 ザ ファウンドリー， エルエルシー 治療薬の送達のためのシステムおよび方法
US10052465B2 (en) 2005-07-22 2018-08-21 The Foundry, Llc Methods and systems for toxin delivery to the nasal cavity
US12433837B2 (en) 2005-07-22 2025-10-07 The Foundry, Llc Systems and methods for delivery of a therapeutic agent
US7794386B2 (en) 2006-03-15 2010-09-14 Allergan, Inc. Methods for facilitating weight loss
US20070237802A1 (en) * 2006-04-11 2007-10-11 Medtronic Vascular, Inc. Inhibition of Calcification on an Endovascular Device
US20080092910A1 (en) * 2006-10-18 2008-04-24 Allergan, Inc. Apparatus and method for treating obesity using neurotoxins in conjunction with bariatric procedures
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
KR101719824B1 (ko) 2008-05-09 2017-04-04 호라이라 인코포레이티드 기관지나무 치료용 시스템, 어셈블리 및 방법
EP2403522B1 (de) 2009-03-06 2015-12-16 Allergan, Inc. Clostridium-toxin zur verbesserung des ejakulats
WO2011041483A2 (en) * 2009-09-30 2011-04-07 Toxcure, Inc. Use of botulinum neurotoxin to treat substance addictions
CN107049479B (zh) 2009-10-27 2020-10-16 努瓦拉公司 具有可冷却的能量发射组件的递送装置
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
CN106618731B (zh) 2009-11-11 2020-08-07 努瓦拉公司 用于处理组织和控制狭窄的系统、装置和方法
WO2011137234A1 (en) * 2010-04-30 2011-11-03 Boston Scientific Scimed, Inc. Therapeutic agent delivery device for delivery of a neurotoxin
US20120207743A1 (en) * 2011-02-14 2012-08-16 Allergan, Inc. Inhibiting Aberrant Blood Vessel Formation Using Retargeted Endopeptidases
CN103517731B (zh) 2011-04-08 2016-08-31 柯惠有限合伙公司 用于去除肾交感神经和离子电渗式药物传递的离子电渗式药物传递系统和方法
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
US10149893B2 (en) 2013-09-24 2018-12-11 Allergan, Inc. Methods for modifying progression of osteoarthritis
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
WO2016040932A1 (en) * 2014-09-12 2016-03-17 Borodic Gary E Longevity enhancement induced by repetitive injections of botulinum toxin (centurion effect)
PT3242884T (pt) 2015-01-09 2021-04-22 Ipsen Bioinnovation Ltd Neurotoxinas catiónicas
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
EP3263710A1 (de) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Herstellung von aktivierten clostridien-neurotoxinen
EP3519430A1 (de) 2016-09-29 2019-08-07 Ipsen Biopharm Limited Hybridneurotoxine
US11116561B2 (en) 2018-01-24 2021-09-14 Medtronic Ardian Luxembourg S.A.R.L. Devices, agents, and associated methods for selective modulation of renal nerves
US20210187194A1 (en) 2018-02-26 2021-06-24 Ipsen Biopharm Limited Use of Ultrasound to Guide Injection of Non-cytotoxic Protease
GB202103372D0 (en) 2021-03-11 2021-04-28 Ipsen Biopharm Ltd Modified clostridial neurotoxins
GB202318884D0 (en) 2023-12-11 2024-01-24 Ipsen Biopharm Ltd Formulation

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5092841A (en) * 1990-05-17 1992-03-03 Wayne State University Method for treating an arterial wall injured during angioplasty
AU4282793A (en) † 1992-04-10 1993-11-18 State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University A microneedle for injection of ocular blood vessels
JP2617407B2 (ja) * 1992-09-14 1997-06-04 キッセイ薬品工業株式会社 血管内膜細胞過剰増殖疾患の予防および治療剤
US6121296A (en) * 1992-11-04 2000-09-19 Albert Einstein College Of Medicine Of Yeshiva University Transition-state inhibitors for nucleoside hydrolase and transferase reactions
US5562907A (en) * 1993-05-14 1996-10-08 Arnon; Stephen S. Method to prevent side-effects and insensitivity to the therapeutic uses of toxins
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US5989280A (en) * 1993-10-22 1999-11-23 Scimed Lifesystems, Inc Stent delivery apparatus and method
ES2159624T3 (es) * 1993-12-28 2001-10-16 Allergan Sales Inc Toxinas botulinicas para el tratamiento de la hiperhidrosis.
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
EP1086702B1 (de) * 1994-05-09 2005-04-13 BINDER, William J. Präsynaptische Neurotoxine gegen Migränekopfschmerzen
US5626562A (en) 1994-11-28 1997-05-06 Devices For Vascular Intervention Drug delivery catheter
US6102904A (en) * 1995-07-10 2000-08-15 Interventional Technologies, Inc. Device for injecting fluid into a wall of a blood vessel
US6261318B1 (en) 1995-07-25 2001-07-17 Medstent Inc. Expandable stent
US5851786A (en) * 1995-09-27 1998-12-22 National Jewish Center For Immunology And Respiratory Medicine Product and process to regulate actin polymerization
CA2192520A1 (en) * 1996-03-05 1997-09-05 Ian M. Penn Expandable stent and method for delivery of same
US6057367A (en) * 1996-08-30 2000-05-02 Duke University Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses
US5939070A (en) * 1996-10-28 1999-08-17 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
US6238872B1 (en) * 1997-04-01 2001-05-29 S.E.T.-Smart Endolumenal Technologies Ltd. Targeted therapy to a biomedical device
CA2308396A1 (en) * 1997-05-14 1998-11-19 Evysio Medical Devices Ulc Expandable stent and method for production of same
US6063768A (en) * 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
CA2308177C (en) * 1997-11-07 2005-01-25 Advanced Bio Prosthetic Surfaces, Ltd. Intravascular stent and method for manufacturing an intravascular stent
AU767047B2 (en) 1998-07-20 2003-10-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Vaccines against (escherichia coli) O157 infection
US6196230B1 (en) * 1998-09-10 2001-03-06 Percardia, Inc. Stent delivery system and method of use
US6293959B1 (en) * 1998-11-16 2001-09-25 Cordis Corporation Balloon catheter and stent delivery system having enhanced stent retention and method
US6270521B1 (en) * 1999-05-21 2001-08-07 Cordis Corporation Stent delivery catheter system for primary stenting
US6241758B1 (en) 1999-05-28 2001-06-05 Advanced Cardiovascular Systems, Inc. Self-expanding stent delivery system and method of use
US6977080B1 (en) * 1999-08-10 2005-12-20 Allergan, Inc. Intrapericardial botulinum toxin treatment for bradycardia
US6767544B2 (en) * 2002-04-01 2004-07-27 Allergan, Inc. Methods for treating cardiovascular diseases with botulinum toxin
GB9922554D0 (en) 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US6239118B1 (en) * 1999-10-05 2001-05-29 Richard A. Schatz Method for preventing restenosis using a substituted adenine derivative
US6264671B1 (en) * 1999-11-15 2001-07-24 Advanced Cardiovascular Systems, Inc. Stent delivery catheter and method of use
US6429189B1 (en) * 1999-12-10 2002-08-06 Botulinum Toxin Research Associates, Inc. Cytotoxin (non-neurotoxin) for the treatment of human headache disorders and inflammatory diseases
US6306162B1 (en) * 1999-12-15 2001-10-23 Advanced Cardiovascular Systems, Inc. Stent delivery system utilizing novel balloon for obtaining variable post-deployment stent characteristics
US6464986B1 (en) † 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6299893B1 (en) * 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US6579847B1 (en) * 2000-05-01 2003-06-17 Imarx Therapeutics Inc. Method and apparatus for vascular neuromuscular blockade
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
WO2002053181A1 (en) 2001-01-04 2002-07-11 University Of Saskatchewan Enterohemorragic escherichia coli vaccine
US20020099356A1 (en) * 2001-01-19 2002-07-25 Unger Evan C. Transmembrane transport apparatus and method

Also Published As

Publication number Publication date
ES2281636T5 (es) 2010-12-17
WO2003084567A1 (en) 2003-10-16
US20060127417A1 (en) 2006-06-15
DE60312309D1 (de) 2007-04-19
HK1070575A1 (en) 2005-06-24
AU2003220511C1 (en) 2008-03-06
US7048927B2 (en) 2006-05-23
EP1490097B1 (de) 2007-03-07
US20030185860A1 (en) 2003-10-02
AU2003220511B2 (en) 2006-11-16
US20040223975A1 (en) 2004-11-11
US7494654B2 (en) 2009-02-24
ES2281636T3 (es) 2007-10-01
DE60312309T3 (de) 2011-02-24
BR0308928A (pt) 2005-01-04
JP2005521735A (ja) 2005-07-21
US20040142005A1 (en) 2004-07-22
JP2009102440A (ja) 2009-05-14
AU2003220511A1 (en) 2003-10-20
KR20040105818A (ko) 2004-12-16
CA2480505A1 (en) 2003-10-16
US6767544B2 (en) 2004-07-27
US7223399B2 (en) 2007-05-29
MXPA04009410A (es) 2005-01-25
JP2013053167A (ja) 2013-03-21
EP1490097A1 (de) 2004-12-29
DE60312309T2 (de) 2007-11-08
EP1490097B2 (de) 2010-08-18

Similar Documents

Publication Publication Date Title
ATE355852T1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
ATE555782T1 (de) Prävention und/oder behandlung von kardiovaskulären erkrankungen und/oder damit zusammenhängender herzinsuffizienz
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
ATE524070T1 (de) Verfahren zur verwendung von aus fettgewebe stammenden zellen bei der behandlung von herz- kreislauf-leiden
SG146666A1 (en) Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
ATE281839T1 (de) Behandlung des kongestiven herzversagens durch vorbehandeltes autologes blut
EP0792156A4 (de) Verfahren zur vorbeugung oder behandlung von vaskulären hämorragien und der alzheimerischen krankheit
ATE432693T1 (de) Kombinationstherapie zur behandlung von diabetes und dadurch bedingten leiden sowie zur behandlung von mittels erhöhung des glp-1-spiegels im blut verbesserten leiden
DE602005026724D1 (de) Verfahren zur verwendung von aus fettgewebe stammenden zellen bei der behandlung von herz-kreislauf-leiden
DE60137635D1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
NO20076121L (no) Behandlinger for kardiovaskulaer sykdom
ATE417639T1 (de) Gerät zur bestimmung der dialyse-effizienz
EA200401070A1 (ru) Способы лечения сосудистых заболеваний
ATE446102T1 (de) Behandlung von gewichtsverlust bei patienten mit entzündlichen darmerkrankungen mittels s. boulardii
ATE349523T1 (de) Verfahren zur verwendung eines humanen il-17 verwandten polypeptids zur behandlung von krankheiten
DE60330888D1 (de) Verwendung von drospirenon zur behandlung von hypertension
ATE356995T1 (de) Verfahren zur identifizierung von mitteln zur behandlung von diabetes
DE60309887D1 (de) Kombination von einem aromatasehemmer mit einem bisphosphonat
DE602004024221D1 (de) Behandlung von entzündlichen darmerkrankungen mit 2-methylen-19-nor-vitamin d verbindungen
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
DE602004030661D1 (de) Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis
EP1143996A4 (de) Methode zur behandlung von chronischen herzerkrankungen
DE60305534D1 (de) Verwendung von docosahexaensäure als wirkstoff bei der behandlung von lipodystrophie
DE60021111D1 (de) Verwendung von fibrinolytischen metallproteinasen zur behandlung von blutgerinseln
ATE546548T1 (de) Verfahren zur prognose des nutzens einer antioxidationshemmenden therapie zur vorbeugung von herz-kreislauf-erkrankungen bei hyperglykämischen patienten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1490097

Country of ref document: EP

RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties